Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $10.7 million.

  • vTv Therapeutics' Operating Expenses rose 6444.82% to $10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year increase of 1935.19%. This contributed to the annual value of $25.2 million for FY2024, which is 119.6% down from last year.
  • Latest data reveals that vTv Therapeutics reported Operating Expenses of $10.7 million as of Q3 2025, which was up 6444.82% from $7.7 million recorded in Q2 2025.
  • In the past 5 years, vTv Therapeutics' Operating Expenses ranged from a high of $11.1 million in Q4 2021 and a low of $4.0 million during Q2 2022
  • In the last 5 years, vTv Therapeutics' Operating Expenses had a median value of $6.5 million in 2025 and averaged $6.6 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 14333.55% in 2021, then tumbled by 4286.74% in 2022.
  • Over the past 5 years, vTv Therapeutics' Operating Expenses (Quarter) stood at $11.1 million in 2021, then plummeted by 42.87% to $6.4 million in 2022, then decreased by 25.9% to $4.7 million in 2023, then increased by 4.29% to $4.9 million in 2024, then skyrocketed by 117.95% to $10.7 million in 2025.
  • Its Operating Expenses was $10.7 million in Q3 2025, compared to $7.7 million in Q2 2025 and $6.5 million in Q1 2025.